Can a breastfeeding mother be prescribed aripiprazole?

Aripiprazole and Breastfeeding

Aripiprazole should generally NOT be given to breastfeeding mothers due to high rates of lactation failure (74%) and insufficient milk production, despite the drug being present in breast milk at relatively low levels.

Critical Evidence from FDA Drug Label

The FDA label for aripiprazole explicitly states that there are reports of poor weight gain in breastfed infants exposed to aripiprazole and reports of inadequate milk supply in lactating women taking aripiprazole 111. The label notes that aripiprazole is present in human breast milk at relative infant doses ranging between 0.7% to 8.3% of the maternal weight-adjusted dosage 11.

The Lactation Failure Problem

The most compelling evidence against aripiprazole use during breastfeeding comes from recent clinical studies:

• In a 2025 multi-site Australian study, 73.5% of mothers on aripiprazole ceased breastfeeding by their last midwife appointment, and only ONE mother (3%) was able to exclusively breastfeed 2. This effect appears to be dose-related.

• A 2025 Indian perinatal psychiatry study found that 74% of women experienced complete lactation failure and 11% had insufficient milk production while on aripiprazole 3. The mean dose was 16.4 mg/day.

• A 2023 Turkish case series reported lactation failure in both cases of aripiprazole exposure during the postpartum period 4.

Why This Happens

Aripiprazole is a partial dopamine agonist with a unique mechanism that lowers prolactin levels 25. Unlike most antipsychotics that increase prolactin, aripiprazole's dopamine agonist activity at D2 receptors suppresses prolactin secretion, which is essential for milk production. This is not a theoretical concern—it translates to real-world lactation failure in the majority of exposed women.

Clinical Decision Algorithm

If the mother is already on aripiprazole during pregnancy:

1. Before delivery: Counsel extensively about the 70-75% risk of lactation failure
2. Consider switching to a prolactin-neutral or prolactin-elevating antipsychotic if clinically stable (e.g., olanzapine or quetiapine, which have better breastfeeding compatibility data)
3. If switching is not possible due to disease severity or treatment resistance:
   • Prepare for formula feeding
   • Do not attempt breastfeeding as primary nutrition source
   • Monitor infant weight closely if any breastfeeding is attempted

If considering starting aripiprazole postpartum:

1. Choose an alternative antipsychotic if breastfeeding is desired
2. Acceptable alternatives for breastfeeding include olanzapine and quetiapine 5
3. Possible under medical supervision: chlorpromazine, haloperidol, risperidone 5

Important Caveats

• The 2020 EULAR rheumatology guidelines 6 emphasize that women should not be discouraged from breastfeeding while taking compatible medications, but aripiprazole does not meet the threshold of "compatible" given the lactation failure data

• While the 2022 AAP breastfeeding guideline 7 states most maternal medications are compatible with breastfeeding, this general principle does not override drug-specific evidence showing harm (in this case, lactation suppression)

• The risk-benefit calculation must prioritize: maternal mental health stability vs. the well-established benefits of breastfeeding for both mother and infant 67

Bottom Line

Aripiprazole causes lactation failure in approximately 3 out of 4 women. If maternal psychiatric stability absolutely requires aripiprazole and no alternative antipsychotic is suitable, formula feeding should be the planned approach. The FDA label's acknowledgment of inadequate milk supply and poor infant weight gain, combined with consistent findings across multiple 2025 studies showing 70-75% lactation failure rates, makes this recommendation clear-cut despite aripiprazole's low transfer into breast milk.